Your browser is no longer supported. Please, upgrade your browser.
SYN Synthetic Biologics, Inc. monthly Stock Chart
SYN [AMEX]
Synthetic Biologics, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.13% Shs Outstand17.09M Perf Week1.54%
Market Cap5.90M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float17.88M Perf Month-0.99%
Income-15.50M PEG- EPS next Q-0.14 Inst Own7.40% Short Float0.12% Perf Quarter-28.26%
Sales- P/S- EPS this Y75.90% Inst Trans-16.63% Short Ratio0.07 Perf Half Y-15.10%
Book/sh-0.31 P/B- EPS next Y21.10% ROA-84.10% Target Price- Perf Year-40.22%
Cash/sh0.56 P/C0.58 EPS next 5Y- ROE- 52W Range0.25 - 0.63 Perf YTD-34.90%
Dividend- P/FCF- EPS past 5Y38.60% ROI- 52W High-47.57% Beta1.70
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low30.85% ATR0.04
Employees11 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)49.60 Volatility8.91% 10.14%
OptionableNo Debt/Eq- EPS Q/Q20.90% Profit Margin- Rel Volume0.69 Prev Close0.32
ShortableYes LT Debt/Eq- EarningsMay 05 AMC Payout- Avg Volume305.56K Price0.33
Recom2.00 SMA20-1.24% SMA501.60% SMA200-21.96% Volume209,399 Change2.87%
Jan-06-17Reiterated FBR & Co. Outperform $5 → $6
May-06-16Reiterated FBR Capital Outperform $10 → $9
Feb-26-16Initiated FBR Capital Outperform $10
Oct-13-15Initiated RBC Capital Mkts Outperform $8
Mar-16-15Downgrade Maxim Group Buy → Hold $3
Mar-02-15Reiterated Maxim Group Buy $6 → $3
Mar-19-14Reiterated Maxim Group Buy $3 → $6
Sep-30-13Initiated Maxim Group Buy $3
Jun-25-13Initiated Ascendiant Capital Markets Buy $2.25
May-15-20 03:28AM  Edited Transcript of SYN earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-13-20 12:20PM  Sýn hf.: Q1 2020 affected by the COVID-19 pandemic GlobeNewswire -8.73%
May-06-20 09:55AM  How Synthetic Biologics, Inc. (NYSEMKT:SYN) Can Impact Your Portfolio Volatility Simply Wall St.
May-05-20 04:15PM  Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results PR Newswire
Apr-28-20 04:30PM  Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020 PR Newswire
Mar-16-20 03:41PM  First human trial for coronavirus vaccine begins today: AP Yahoo Finance Video
Feb-26-20 12:29PM  Results in line with outlook GlobeNewswire
Feb-23-20 02:26PM  Edited Transcript of SYN earnings conference call or presentation 20-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-20-20 04:15PM  Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results PR Newswire
Feb-07-20 04:30PM  Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American PR Newswire -5.75%
Feb-06-20 01:53PM  We Think Synthetic Biologics (NYSEMKT:SYN) Needs To Drive Business Growth Carefully Simply Wall St. +8.17%
Jan-07-20 07:00AM  Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients PR Newswire
Dec-30-19 05:54AM  Sýn hf.: Financial calendar 2020 GlobeNewswire
Dec-24-19 07:29AM  Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements GlobeNewswire
Nov-30-19 09:39AM  Is Synthetic Biologics Inc (SYN) Going To Burn These Hedge Funds ? Insider Monkey
Nov-27-19 04:30PM  Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan PR Newswire
Nov-21-19 12:21AM  Edited Transcript of SYN earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 11:23AM  Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements GlobeNewswire
Nov-06-19 12:02PM  Sýn hf.: Best operating profit of the year GlobeNewswire
Nov-04-19 04:10PM  Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results PR Newswire +6.28%
Oct-28-19 04:30PM  Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 PR Newswire
Sep-26-19 07:00AM  Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) PR Newswire +12.24%
Sep-06-19 11:24AM  Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market? Simply Wall St.
Sep-01-19 10:50PM  Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-28-19 01:12PM  Sýn hf.: Financial results below expectations but positive outlook GlobeNewswire +5.92%
Aug-20-19 09:46AM  Sýn hf.: Change in guidance GlobeNewswire +6.15%
Aug-08-19 04:15PM  Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results PR Newswire
Aug-01-19 07:00AM  Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 PR Newswire
Jul-01-19 07:00AM  Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire
May-27-19 03:14PM  Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It Simply Wall St.
May-24-19 10:25AM  Sýn hf.: Notification of related party trading GlobeNewswire
May-22-19 12:55PM  Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 06:02PM  Synthetic Biologics: 1Q Earnings Snapshot Associated Press
04:10PM  Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results PR Newswire
Apr-30-19 04:30PM  Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019 PR Newswire
Apr-20-19 03:38AM  Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 04:10PM  Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results PR Newswire
03:05PM  Sýn hf. : Q4 Investors presentation GlobeNewswire
02:55PM  Sýn hf. : Changes in management of Sýn hf. GlobeNewswire
02:53PM  Sýn hf. : Merged company completes its first full year under challenging market conditions GlobeNewswire
Feb-26-19 10:38AM  Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F GlobeNewswire
Feb-19-19 04:30PM  Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019 PR Newswire
Jan-03-19 07:00AM  Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored PR Newswire
Dec-18-18 10:38AM  Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-18 12:00PM  Orchestra BioMed Appoints C. Evan Ballantyne as Chief Financial Officer GlobeNewswire
Nov-27-18 08:20AM  Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-22-18 09:10AM  New Trends in Healthcare Push Stocks Higher: 5 Picks Zacks
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE +5.88%
07:00AM  Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development PR Newswire
Nov-08-18 06:02PM  Synthetic Biologics: 3Q Earnings Snapshot Associated Press
04:10PM  Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results PR Newswire
Oct-30-18 04:30PM  Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018 PR Newswire
Oct-18-18 08:40AM  Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta? Simply Wall St.
Oct-15-18 01:30PM  Synthetic Biologics Announces Closing of $18,639,000 Public Offering PR Newswire
Oct-12-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Hyatt Hotels, E.W. Scripps, Cardtronics, Lincoln National, Synthetic Biologics, and Herc New Research Emphasizes Economic Growth GlobeNewswire
Oct-11-18 09:07AM  Synthetic Biologics Prices $18,000,000 Public Offering PR Newswire -38.22%
Sep-30-18 09:26AM  Who Are The Major Shareholders Of Synthetic Biologics Inc (NYSEMKT:SYN)? Simply Wall St.
Sep-06-18 07:00AM  Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C PR Newswire
Aug-30-18 04:10PM  Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference PR Newswire -5.63%
Aug-23-18 09:50PM  Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -7.46%
Aug-17-18 02:32PM  What Goes Through The Mind of A Trader When Taking A Position? Benzinga +7.84%
Aug-13-18 07:55AM  Consolidated Research: 2018 Summary Expectations for Fulton Financial, Leidos, Principal Financial Group, Quanta Services, Synthetic Biologics, and Sterling Fundamental Analysis, Key Performance Indications GlobeNewswire -18.62%
Aug-08-18 05:31PM  Synthetic Biologics: 2Q Earnings Snapshot Associated Press
04:10PM  Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results PR Newswire
02:30PM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
12:27PM  Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc (NYSEMKT:SYN)? Simply Wall St.
Aug-01-18 05:05PM  Synthetic Biologics Announces Reverse Stock Split PR Newswire +9.67%
Jul-31-18 07:00AM  Synthetic Biologics to Report Second Quarter 2018 Operational Highlights and Financial Results on August 8, 2018 PR Newswire
Jun-20-18 07:50AM  Stock Performance Review on Sesen Bio and Three Other Biotech ACCESSWIRE
May-22-18 07:00AM  Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American PR Newswire
May-21-18 07:25AM  Stock Performance Review on Tesaro and Three Other Biotech Industry ACCESSWIRE
May-14-18 11:52AM  Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
07:40AM  Report: Developing Opportunities within Crown, American Equity Investment Life Holding, Acco Brands, Synthetic Biologics, Universal Display, and Lamb Weston Future Expectations, Projections Moving into 2018 GlobeNewswire
May-09-18 07:48AM  Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway Benzinga +11.96%
05:11AM  Synthetic Biologics: 1Q Earnings Snapshot Associated Press
May-08-18 04:05PM  Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results PR Newswire
Apr-26-18 07:00AM  Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018 PR Newswire +9.42%
Apr-23-18 07:00AM  Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection PR Newswire -30.33%
Mar-09-18 08:25AM  Report: Exploring Fundamental Drivers Behind EOG Resources, Alteryx, Synthetic Biologics, Extreme Networks, Knight-Swift Transportation Holdings Inc., and Select Medical New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-07-18 04:10PM  Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan PR Newswire +25.75%
Feb-22-18 08:21PM  Edited Transcript of SYN earnings conference call or presentation 22-Feb-18 1:30pm GMT Thomson Reuters StreetEvents -10.17%
06:47AM  Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results PR Newswire
06:20AM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 04:10PM  Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018 PR Newswire -5.08%
Jan-02-18 04:30PM  Synthetic Biologics to Present at the Biotech Showcase 2018 Conference PR Newswire
Dec-05-17 08:00AM  Synthetic Biologics Announces Management Changes PR Newswire
Nov-20-17 08:30AM  ImmunoPrecise Realigns Senior Management CNW Group
Nov-15-17 07:40AM  New Research Coverage Highlights Synthetic Biologics, ReShape Lifesciences, Estée Lauder, Old Republic International, Vulcan Materials, and Taylor Morrison Home Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-02-17 06:44PM  Edited Transcript of SYN earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents -11.76%
Nov-01-17 06:37PM  Synthetic Biologics reports 3Q loss Associated Press -5.21%
04:10PM  Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results PR Newswire
12:10PM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Oct-25-17 07:00AM  Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017 PR Newswire
Sep-18-17 08:31AM  Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher Zacks +10.34%
08:20AM  Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical ACCESSWIRE
Sep-12-17 07:00AM  Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing PR Newswire -5.62%
Sep-06-17 07:30AM  Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com ACCESSWIRE
Aug-29-17 07:00AM  Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 PR Newswire +11.81%
Aug-21-17 04:05AM  Edited Transcript of SYN earnings conference call or presentation 3-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:08AM  Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT Zacks
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHALLCROSS STEVEN ACEO and CFOAug 23Buy0.4250,00020,78550,000Aug 26 05:00 PM